NCAM1 and myeloid sarcoma: Moreover, the frequency of CD56+ T cells markedly increased in all of the four relapsed F-MS patients whose samples were available at relapse; the frequency of CD56+ T cells increased to 68.3%, 60.9%, 47.4%, and 41.2%.